Product safety study for a citrate calcium anticoagulation system

Submission date	Recruitment status	[X] Prospectively registered
04/02/2009	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
27/02/2009	Completed	Results
Last Edited	Condition category	Individual participant data
27/02/2009	Urological and Genital Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Dieter Falkenhagen

Contact details

Dr.-Karl-Dorrek-Str. 30 Krems Austria 3500

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Product safety study for a citrate calcium anticoagulation system: an interventional single-arm open-label trial

Study objectives

Primary goal of the study is the proof of functionality and safety of a algorithm for automated software controlled citrate-calcium anticoagulation. The hypothesis of the authors is that the

specification of a target calcium value in the anticoagulated extracorporeal circuit is associated with a high functionality and a high safety using a citrate calcium anticoagulation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

To be submitted to the Ethics Committee of Upper Austria, Wagner Jauregg Mental Health Hospital as of 04/02/2009.

Study design

Interventional single-arm open-label trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic dialysis

Interventions

Regional anticoagulation with trinatrium citrate and substitution with calcium chloride. Five treatments per patient over 2 weeks, with a duration of 4 hours per treatment planned.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The following will be assessed at baseline, after 15 minutes and then every 60 minutes during treatment (maximum treatment duration is 4 hours):

- 1. Evaluation of the effectiveness of anticoagulation based on coagulation parameters
- 2. Time dependency of citrate and calcium values in the extracorporal circuit
- 3. Anticoagulation state in the extracorporal circuit
- 4. Citrate and calcium level in the patients blood

Key secondary outcome(s))

The following will be assessed at baseline and end of each treatment period: D-Dimer, Mg2+ and sodium concentration

Completion date

31/08/2009

Eligibility

Key inclusion criteria

- 1. Both males and females, age: 19 to 65 years
- 2. Chronic dialysis patients
- 3. Haematocrit (Hkt): 30 bis 45 %
- 4. Ca2+: 1.0-1.30 mmol/l
- 5. Weight: >60 kg

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

- 1. High risk of bleeding, pallets count <40,000/µl
- 2. Haemoglobin <9 g/dl
- 3. Alkalosis pH > 7.50
- 4. Acidosis pH <7.35
- 5. Liver insufficiency
- 6. Respiratory insufficiency
- 7. Patients with cardiovascular problems
- 8. Oral anticoagulans
- 9. Hepatitis C, B, HIV patients

Date of first enrolment

01/05/2009

Date of final enrolment

31/08/2009

Locations

Countries of recruitment

Austria

Study participating centre Dr.-Karl-Dorrek-Str. 30

Krems

Austria

3500

Sponsor information

Organisation

Danube University Krems (Austria)

ROR

https://ror.org/03ef4a036

Funder(s)

Funder type

University/education

Funder Name

Danube University Krems (Austria)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing? Participant information sheet 11/11/2025 No

Participant information sheet Yes